Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging therapeutic options for periorbital and orbital cutaneous basal and squamous cell carcinomas.

Orbit (Amsterdam, Netherlands)·2022
Same author

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.

Science immunology·2020
Same author

Getting to the End Zone With Medicare for All.

The Journal of ambulatory care management·2019
Same author

Estimating the value of intravenous calcium and magnesium in ameliorating oxaliplatin-induced neuropathy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2014
Same author

Adjuvant chemotherapy for rectal cancer.

The Lancet. Oncology·2014
Same author

Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo.

Experimental hematology & oncology·2013

Related Experiment Video

Updated: May 20, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Radiotherapy plus chemotherapy in muscle-invasive bladder cancer

Carl D Atkins, Stephen H Wrzesinski

    The New England Journal of Medicine
    |July 27, 2012
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
    08:43

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

    Published on: July 28, 2012

    Related Experiment Videos

    Last Updated: May 20, 2026

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
    08:43

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

    Published on: July 28, 2012